266 related articles for article (PubMed ID: 30567527)
1. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
Conteduca V; Gurioli G; Rossi L; Scarpi E; Lolli C; Schepisi G; Farolfi A; De Lisi D; Gallà V; Burgio SL; Menna C; Amadori A; Losi L; Amadori D; Costi MP; De Giorgi U
BMC Cancer; 2018 Dec; 18(1):1267. PubMed ID: 30567527
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
Rosa DD; Awada A; Mano MS; Selleslags J; Lebrun F; Gil T; Piccart MJ; D'Hondt V
Arch Gynecol Obstet; 2008 Nov; 278(5):457-62. PubMed ID: 18273626
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
[TBL] [Abstract][Full Text] [Related]
7. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer.
Lee HJ; Kim HS; Park NH; Chung HH; Kim JW; Song YS
Cancer Res Treat; 2013 Mar; 45(1):40-7. PubMed ID: 23613669
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
10. [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].
de Gramont A; Tournigand C; Louvet C; André T; Molitor JL; Raymond E; Moreau S; Vignoud J; Le Bail N; Krulik M
Rev Med Interne; 1997; 18(10):769-75. PubMed ID: 9500010
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
Petrioli R; Francini E; Roviello F; Marrelli D; Miano ST; Fiaschi AI; Laera L; Bellini MA; Roviello G
J Geriatr Oncol; 2015 Sep; 6(5):380-6. PubMed ID: 26228711
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
13. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.
Stein SM; Tiersten A; Hochster HS; Blank SV; Pothuri B; Curtin J; Shapira I; Levinson B; Ivy P; Joseph B; Guddati AK; Muggia F
Int J Gynecol Cancer; 2013 Nov; 23(9):1577-82. PubMed ID: 24172094
[TBL] [Abstract][Full Text] [Related]
15. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
[TBL] [Abstract][Full Text] [Related]
16. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
17. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
18. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.
Wang J; Chang J; Yu H; Wu X; Wang H; Li W; Ji D; Peng W
Cancer Chemother Pharmacol; 2013 Apr; 71(4):905-11. PubMed ID: 23370661
[TBL] [Abstract][Full Text] [Related]
20. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
